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Introduction 
Lung Cancer  
Epidemiology 
Lung cancer is one of the most common cancers in the world, with the highest 
morbidity and mortality among malignancies disease.  
A 2008 world cancer report issued by International agency for research on cancer 
(IARC) shows that lung cancer accounts for 16,5% of all new cancer cases, with a percentage 
of mortality of 22,5% respect to all cancer, confirming its as one of the leading causes of 
cancer-related mortality worldwide1. 
The population segment most likely to develop lung cancer is people aged over 50 
who have a history of smoking. Although the relative incidence of lung cancer is decreasing, a 
recent study on cancer mortality in the countries of the European Union predicted in 2012 a 
decrease of mortality from lung cancer by 10% in males (while remaining the leading cause of 
death by cancer) but an increase by 7% in females (thus becoming the second leading cause of 
cancer mortality)2.  
This change is in part due to the different trend of smoking in both sexes of the last 
two decades, which shows a moderated increment of use of tobacco in females. 
The prognosis for patients diagnosed with lung cancer is poor, with overall five year 
survival remaining below 15,7%. This is partly attributable to relatively ineffective methods 
for early detection and lack of curative treatment for advanced disease. The 5-year relative 
survival rate varies markedly depending on the stage at diagnosis, from 49% to 16% to 2% for 
patients with local, regional, and distant stage disease, respectively.  
 
Etiology 
Although the etiology of lung cancer is still partially unknown, inhaled carcinogens 
are known to be important predisposing causes. Particularly, about 83% of lung cancers are 
directly linked to smoking and inhaling the carcinogens in tobacco smoke3; the risk is higher 
with an increase of number of cigarettes smoked/day and earlier age of smoking. 
However, numerous other substances, occupations, and environmental exposures have 
been linked to lung cancer, such as high levels of pollution, radiation, and asbestos.  
Finally, individual differences in susceptibility to lung carcinogens may be the result 
of genetic predisposition to lung cancer4. Several evidences shows a correlation between a 
genetic predisposition, inherited or acquired during life, the exposure to certain environmental 
factors and the onset of lung malignancies. 
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Histology 
Histologically, lung cancers are classified by the size and the appearance of the 
malignant cells in two main types: small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC)5. Mostly of lung cancers are carcinomas, malignancies that arise from 
bronchial epithelial cells. 
SCLC represent about 15 percent of all lung cancers. This is an aggressive cancer 
made up by fast-growing small cells that can spread to other organs. Generally it starts in the 
bronchi, growing in the central part of the lungs. SCLC is more responsive to chemotherapy 
and radiation therapy than other cell types of lung cancer, but a definitive cure is difficult to 
achieve and the prognosis is closely linked to the extent of disease by time of diagnosis. 
NSCLC represent the remaining 85 percent of lung cancer cases. NSCLC arises from 
the epithelial cells of the lung of the central bronchi to terminal alveoli. It generally grows and 
spread more slowly than SCLC. This class comprises three different histological subtypes 
which correlates both for the site of origin and the similar approaches to diagnosis, staging, 
prognosis, and treatment. 
The three histological subtypes are: 
• Squamous cell carcinoma (SCC) or epidermoid carcinoma represents 30 percent of 
lung cancers; this is a central tumor that usually starts near a central bronchus. Any of 
morphological features include intercellular bridges and individual cell keratinization. 
SCC is the most common type of lung tumor in men, smokers; 
• Adenocarcinoma (AC) represents now the dominant histotype of all lung cancers 
(35% ); it predominantly arises in peripheral lung tissue and is histologically 
characterised by the presence of glandular differentiation and/or mucin production, 
although often it shows a mixed histological pattern. AC is the most common type of 
lung cancer in women, nonsmokers;  
• Large-cell undifferentiated carcinoma (LCC) represents approximately 10-15 
percent of all lung cancers. LCC is a rapidly growing cancer arising near the outer 
edges or surface of the lungs. The LCC classification is seldom used today and has 
been replace by a more specific classification based on specific cancer cell type (such 
as large cell neuroendocrine carcinoma). 
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Clinical and therapeutical aspects 
Therapeutical approaches for lung cancer are determined by histology, stage, and 
general health and comorbidities of the patient. The main lung cancer treatments are surgery, 
chemotherapy and radiation. Usually, this is no single treatment for lung cancer, but patients 
often receive a combination of therapies and palliative care. 
Generally, surgery is performed for patients with resectable disease, classified on the 
size of the primary tumor, the potentially involvement of lymph node and metastases. The 
surgical resection of cancer can be followed by chemotherapeutic or radiation treatment.  
For patients with unresectable disease the treatment with radiation and/or 
chemotherapy permits to treat localized lesions and may achieve long-term survival.  
SCLC has the most aggressive clinical course of any type of pulmonary tumor; it 
responds well to chemotherapy and it is not generally treated with surgery. Today the standard 
of SCLC care is the combination of chemotherapy with thoracic radiation therapy (TRT): 
evidences show that TRT increases survival by approximately 5% over chemotherapy 
alone6,7. 
On the contrary, NSCLCs are relatively insensitive to chemotherapy and radiation 
therapy compared with SCLC. The elective treatment for early stage NSCLC is the complete 
excision of neoplastic mass that can be followed by chemotherapeutic or local radiation 
treatment. 
A new era in the treatment of lung cancer started with the identification of genetic 
mutations in any subtypes of this cancer8. This discovery has led to the development of new 
molecular target therapy associated with specific cell types and subtypes. Targeted therapies 
are designed to only treat cancer cells. These include monoclonal antibodies, anti-
angiogenesis agents and growth factor inhibitors that disallow the cancerous cells to grow.   
In particular, genetic abnormalities of potential relevance to treatment choises are 
identified easily in NSCLC, in particular in a subset of adenocarcinoma. Among others, the 
most significant mutations found are: 
• Specific mutations in genes encoding components of the epidermal growth factor 
receptor (EGFR)9,10;  
• Translocations involving the anaplastic lymphoma kinase (ALK)-tyrosine kinase 
receptor, which are sensitive to ALK inhibitors11;  
• Amplification of MET (mesenchymal epithelial transition factor), which encodes the 
hepatocyte growth factor receptor.  
8 
 
These mutations may define mechanisms of drug sensitivity and primary or acquired 
resistance to kinase inhibitors: i.e MET amplification has been associated with secondary 
resistance to EGFR tyrosine kinase inhibitors12. 
The development of these new therapeutic strategies has improved the survival of lung 
cancer patient but prognosis is still poor. This is probably due to lack of knowledge of lung 
cancer biology and its carcinogenesis.  
 
Human Stem Cells  
It has been largely demonstrated the presence of a population of adult stem/progenitor 
cells (SC) in all human organs that is responsible for both maintenance of tissue homeostasis 
and repair tissue after injury. 
SC population is capable of unlimited self-renewal and can develop into more 
differentiated cell types (pluripotential)13, but in normal condition its turnover is relatively 
slow. They are concentrated in protected areas of each tissue called niches. The stem cell 
niche comprises not only stem cells but also a number of other differentiated cell types, 
diverse extracellular matrix proteins (ECMs), and other growth factors; the adhesion between 
stem cells and more differentiated cells appears to be important for the self-renewal of stem 
cells, the maintenance of their pluripotential and their differentiation into mature cells14. 
An alteration of niche micro-environment or a deregulation of intracellular pathway 
may compromise the physiological function of the organ. In particular, several studies have 
demonstrated that cancer stem cells exhibit many stem cell properties: this involves the 
possibility that carcinogenesis process may start from a stem/progenitor resident cell. 
 
Human Lung Stem Cells 
SC are found in a number of adult tissues, including the lungs15. 
The lung is an organ anatomically complex, because is composed by multiple 
anatomic region, each characterized by a unique cellular organization and unique repair 
mechanism. So, also epithelial stem cell populations in the lung are classically subdivided by 
region16. 
The most proximal conducting airways display a columnar ephitelium constituted by 
ciliated cells, secretory Clara cells, basal cells, and submucosal glandular epithelium: the stem 
cell compartment in this area has been identified in the basal and parabasal cell. 
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In the distal bronchiolar airway there is an epithelial surface with no basal cells and an 
increasing ratio of secretory Clara cells, that are the stem compartment able to proliferate after 
injury.  
At the broncho-alveolar duct junction the airway epithelium changes to organized into 
distal functional alveoli. These structures are formed by type I pneumocytes, that form the 
gas-exchange surface area of the lung, and cuboidal surfactant-expressing pneumocytes type 
II, which were identified as the stem compartment of this area of lung parenchyma. 
 
 
 
 
 
Schematic representation of lung epithelial progenitor cells and their spatial location in the lung parenchyma. 
 
 
Cancer stem cell and lung cancer 
The classification of pulmonary SC above can reflect the specific parenchymal 
distribution of lung cancer and support the idea that oncogenesis process can be start from a 
normal resident stem cell. 
Several studies suggest that pulmonary stem cell signaling and differentiation 
pathways are maintained within distinct cancer types, and that the destabilization of this 
signaling is related to the development of region-specific lung cancers.  
In particular, in many experiment conducted with different murine models the lung 
cancer development seems to follow a proximal-to-distal distribution pattern: from the trachea 
to distal lung parenchyma, major tumor types include squamous cell carcinomas (SCCs), 
small cell lung carcinomas (SCLCs), and adenocarcinomas/bronchoalveolar carcinomas (AC). 
This regional segregation of lung cancer subtypes suggests that only specific cell populations 
and/or pulmonary environments are capable of supporting tumor growth17.  
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It was supposed that these different classes of cancer arise from specific resident stem 
cells located in restricted areas of lung parenchyma. For example, lung SCC, usually located 
on central part of the lung, is rich of basal elements recognized by CK5 expression and then it 
may derive from basal stem cell of trachea; also for AC, usually located in the distal bronco-
alveolar district, there are evidences of its origin from the regional bronchioalveolar stem cells 
(BASCs)18. 
From these literature data results necessary a better understanding of the relationship 
among stem cell regulation, cellular mutation, and lung cancer oncogenesis, expecially to 
develop the next wave of lung cancer therapies. 
 
Cancer initiating cell (CIC) 
The first evidence of stem cells involvement in the genesis and progression of several 
cancer types have been observed in hematological, brain and breast malignancies19,20,21. 
In particular, recent studies22,23 have introduced the new concept of cancer initiating 
cells (CICs) referring to a subpopulation of cancer stem cell (CSC) pool that seems able to 
drive each step of tumor reprogramming, from the beginning of growth and metastasis, and 
showing radio- and chemotherapy resistance. 
CICs were also identified for their capacity to generate in vivo a neoplasia with the 
same morphological features of the original tumor, proving their unique abilities to self-
renewal and differentiate into all cell compartment necessary for tumor growth. 
Despite of functional characterization of CICs, many other informations on their origin 
and molecular pattern are required to consider them as a target of cancer therapies. In 
particular, the identification of a reliable panel of markers for CSC and CIC populations, 
cancer and organ-specific, may lead to a better understanding of the pathogenesis of cancer 
and, considering the probable involvement of both population, CICs in particular, in cancer 
establishment to design a specific drug therapy against them. 
 
Epithelial-To-Mesenchymal transition 
The current knowledges on CICs and their dominant role in the cancer progression 
may explain the high aggressiveness and invasive potential of some cancer types. 
In particular, in reference to lung cancer progression and metastasis, recent studies 
have related the invasive potential of cancer cells to activation of the Epithelial-to-
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Mesenchymal Transition; on the other hand, the establishment of disseminated metastasis was 
associated to the inverse process of Mesenchymal-to-Epithelial Transition (MET)24,25.  
Assuming that mostly of lung cancers have an epithelial origin, the EMT/MET 
processes are thought to be an important mechanism for promoting cancer invasion and 
metastasis.  
Epithelial cells are characterized by well-developed, intercellular contacts, whereas 
mesenchymal cells seldom form intercellular junctions. 
For this reason, the EMT requires transcriptional reprogramming to downregulated 
expression of cell adhesion molecules and simultaneously to upregulated proteins involved in 
motile cell state characteristic of mesenchymal-like phenotype.  
The EMT is a critical process activated during the embryonic development; if refers to 
adult differentiated epithelial cells and in particular to lung cancer progression, some 
differences have been reported. 
For the lung cancer, two main hallmarks of EMT are loss of E-cadherin, a key 
mediator of cell–cell junctions and the increase of expression of the surface motile protein 
Vimentin. Numerous studies have related the inverse relation between these two markers and 
the gain of tumor invasiveness in cancer cells26,27,28 . 
In particular, loss of E-cadherin appears to be a prerequisite for tumor progression and 
not just a consequence of tumor dedifferentiation. Some studies on experimental models show 
that during tumorigenesis, E-cadherin expression was shown to decrease with tumor 
progression, but it maintenance arrested tumor development29.  
Ectopic expression of E-cadherin results sufficient to suppress cancer cell invasion in 
vitro and in vivo, and the knock-down converts cell from non-invasive to invasive phenotype. 
However, the restoration of E-cadherin expression may be insufficient to reverse EMT and 
restore the epithelial phenotype. This imply that E-cadherin has a tumor suppressive function 
and is not simply a marker of tumor differentiation. 
Furthermore, EMT activation was related to cell acquisition of stem properties30 and 
also with a decrease of cell drug sensitivity31,32;these two evidences confirm the hypothesis 
that a cancer cell undergo EMT process may become a metastatic drug-resistant cancer 
progenitor cell, or a metastatic CSC. 
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Aim of the study 
Lung cancer remains the first cause of death among all human malignancies. Although 
the identification of several etiologic factors involved in this cancer development, the 
molecular and biologic mechanisms responsible of the beginning and the amplification of 
lung cancer cells are still partially unknown. 
Recent studies have related the lung stem cell pool, physiologically responsible of 
maintenance of tissue homeostasis, to the cancer development, given that cancer stem cells 
present many features in common with the healthy stem compartment. In particular, a 
subpopulation of these cancer stem cell, called CICs, are responsible of cancer growth and 
metastasis; for these reasons, this population may be a new potential therapeutic target that 
may change the natural history of the lung tumor. Anyway, more investigation are necessary 
for a phenotypic characterization of CIC, related to cancer type. 
A research project named “Lung Cancer-Initiating Cell” (LCIC) has made in our 
laboratory with the purpose of isolate and characterize a population of lung stem cells and 
lung cancer stem cells from human samples of subjects undergoing lobectomy for lung 
cancer. From cancer fragments, we have obtained several cell populations associated to 
stromal, endothelial and epithelial compartment of lung parenchyma. 
In particular, this study was focused on the lung epithelial compartment: these cells 
cover the pulmonary surface of almost all districts of lung. For this reason, the lung stem cell 
niches comprise, among others, the epithelial stem cells, that are involved in the regeneration 
of epithelial compartment, but also in the cancer development. Indeed, almost all lung cancer 
have an epithelial origin. 
On these evidences, this work shows the results relative to the isolation and 
characterization of an epithelial cell line isolate from a lung adenocarcinoma. The 
investigation of cell line properties was conduct in two steps: an in vitro characterization of 
cellular phenotype and growth characteristic, and an in vivo step to test the tumorigenic 
potential of this cell line through xenografts induction. 
If the epithelial compartment is responsible of beginning and tumor progression, the 
possibility of isolate and characterize this cell compartment especially from more aggressive 
lung cancer may open new therapeutic options based on a personalized drug-therapy. 
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Material and Methods 
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The present investigation conforms with the National ethical guidelines (Italian 
Ministry of Health; D.L.vo 116, January 27, 1992) and the‘Guide for the Care and Use of 
Laboratory Animals’ published by the US National Institutes of Health (NIH publication no. 
85–23, revised 1996). Specifically, informed consent was obtained from each patient to allow 
the collection of lung cancer samples. 
In vitro studies 
Case study 
The study population consisted of 86 patients admitted to the Unit of Thoracic 
Surgery, University of Parma with lung cancer diagnosis and treated primarily with surgical 
resection of neoplastic area. 
For the following analysis, lung tissue was collected and transported under sterile 
condition to the Department of Pathologic Anatomy, where it was sampled under hood at 
laminar flow by the medical staff. Particularly, from the resection were obtained portions of 
neoplastic and healthy tissue, that were put in sterile buffer in order to perform cell isolation. 
 
Cell isolation and culture 
Lung tissue fragments of 1-2 gr., obtained from lung cancer or distal parenchyma, 
were separately processed following the same protocol. 
The tissue fragment was first minced using surgical scissors and after this first 
mechanical digestion the micro-fragments were digested in a solution of Accutase® (Sigma-
Aldrich, Milan, Italy) for 75 minutes in a shaking bath at 37°C. At the end of enzymatic 
digestion, the tissue fragments were removed using a nylon filter with pores of 100 µm and 
the cell suspension was centrifuged at 240g for 5 minutes. 
The pellet was then suspended in culture medium Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 5% Fetal Bovine Serum (FBS, Sigma-Aldrich, Milan, 
Italy), 1% Penicillin-Streptomycin (P/S, Sigma-Aldrich, Milan, Italy), 1% Insulin-Transferrin-
Sodium Selenite (I/T/S, Sigma-Aldrich, Milan, Italy), and specific growth factors as 10 ng/ml 
Basic-Fibroblast Growth Factor (b-FGF, Sigma-Aldrich, Milan, Italy), 10 ng/ml Epidermal 
Growth Factor (EGF, Sigma-Aldrich, Milan, Italy) and 1% Non Essential Amino Acids 
(NEAA) and seeded in 6 well plates at 37°C-5% CO2. 
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Twenty-four hours after plating the debris and the non-adherent cells (erythrocytes, 
leucocytes, death cells) were removed by washing twice with PBS; fresh culture medium was 
then added to cell culture.  
Cell monolayer was daily observed using an inverted microscope (Olympus CK40, 
Japan) and fresh culture medium was changed twice a week.  
In the first week was observed an heterogeneous cell population mainly constituted of 
stromal and epithelial cells.  
 
Cell enrichment  
Tumor Epithelial Cells (TEpCs) were easily recognized by morphology and growth in 
colonies from the stromal adherent cells showing a fibroblast-like shape. 
To obtain a pure population of both these cell lines we took advance from their 
different resistance to Trypsin. The stromal population was more sensitive to trypsin activity 
and then was be quickly and firstly removed by culture dishes. Then fresh enzyme was added 
to adherent TEpC to favour cells detachment from the dishes and their expansion. 
The obtained suspensions of stromal cells and TEpCs were separately replaced in a 
new culture dish maintaining the growth condition previously described. The evaluation of 
cell growth was performed by daily observation and cell count. 
Both these cell line were amplified for several passages and cryo-preserved in aliquots 
in a medium composed by FBS supplemented with 1% Dimethylsulphoxide (DMSO, Sigma-
Aldrich, Milan, Italy). 
 
Calu-3 cell culture 
Calu-3 (ATCC® HTB-55™) is a bronchial epithelial cell line derived from a human 
lung adenocarcinoma of a 25 years-old caucasian male. 
This cell line has been extensively researched and it was largely employed for in vitro 
and in vivo experimental model of respiratory system disease, including lung tumour. 
Concerning this, the most important features of Calu-3 are the k-ras gene mutation, the 
amplification of the human epidermal growth factor receptor 2 (HER2/neu) while it was wild 
type for Epidermal Growth factor receptor (EGFR); also it was documented the absence of Y 
human chromosome in these cells. 
Primary Calu-3 were purchased from American Type Culture Collection (ATCC® 
Milan, Italy) and cultured in tissue culture flasks with Dulbecco's modified Eagle's medium 
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(DMEM) supplemented with 10% Fetal Bovine Serum (FBS, Sigma, St. Louis, MO), 1% 
Penicillin-Streptomycin (P/S, Sigma, St. Louis, MO) and 1% Non Essential Amino Acids 
(NEAA) and placed at 37°C-5% CO2. 
The cell line was amplified and cryo-preserved at any passage in aliquots in a medium 
composed by FBS supplemented with 1% Dimethylsulphoxide (DMSO, Sigma, St. Louis, 
MO). 
 
Immunophenotypic characterization by FACS Analysis 
Fluorescence-Activated Cell Sorting (FACS) analysis is a fast and reliable method for 
characterizing and isolating specific cell subpopulations based on fluorescent labeling. One 
single analysis allows to collect several information on the entire population analyzed as cell 
number or mean dimension; it also permits the detection of specific biomarker and the sorting 
of a specific cell subpopulation from the initial pool. 
For this study FACS analysis was performed on TEpC and stromal cell populations in 
order to evaluate the qualitative and quantitative expression of specific biomarker. Cells were 
harvested from culture flasks by trypsinization and suspended at density 1x106 cells/ml in a 
simple sterile buffer. 
At the cell suspension was added 1 µg/106 cells of fluorochrome-conjugated (FITC or 
PE) monoclonal antibodies with determined specificity against stem cells antigens (CD117, 
CD133), mesenchymal (stromal) cell surface antigens (CD44, CD73, CD90, CD105), 
hematopoietic cell surface antigens (CD45), and the selective Epithelial-Cell Adhesion 
Molecule (EpCAM) a  transmembrane glycoprotein expressed exclusively in epithelia and 
epithelial-derived neoplasms. 
 To test the cell vitality it was added to each cell suspension the DNA dyes 7-amino 
actinomycin D (7AAD), while for the negative controls was used a fluorochrome-conjugated 
antibody with irrelevant specificity. 
The cell suspensions were incubated for twenty minutes at 4°C. Labelled cells were 
then washed with PBS to remove the exceed antibodies and centrifuged for six minutes at 
240g at 4°C.  
The pellet was analyzed by a FACS-Diva software. (FACScanto II) by acquiring at 
least 10,000 events.  
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The percentage of cells positive for each surface antigen (red line histograms) 
considered was obtained by subtracting the corresponding values of negative controls (green 
line histograms). 
 
Immunocytochemical analysis 
The immunocytochemical analysis on TEpC and Calu-3 cell lines was conducted on 
fluorescence and optical preparations. The two techniques diverge from each other for the 
revelation method.  
For the fluorescence revelation is used a secondary antibody conjugated to a 
fluorochrome (Fluoresceine Isothiocyanate- FITC, Tetramethyl Rhodamine Isothiocyanate -
TRITC or Cyanide 5 -CY5) and the nuclear counterstaining is performed with DAPI (4’,6-
diamidine-2-phenyndole, Sigma-Aldrich, Milan, Italy). Slides were mounted with 
fluorescence mounting medium Vectashield (Vector, USA). 
For the optical preparation the secondary antibody is a peroxidase-conjugated 
streptavidin that catalyze the oxido-reduction reaction of the chromogenic substrate (DAB, 3-
3’ diaminobenzidin for 5 minutes). All sections were counterstained with Haematoxylin. 
 
Immunofluorescence staining 
In order to confirm the epithelial phenotype of the isolated TEpCs an 
immunocytochemical analysis was performed on this line and on Calu-3 as control line. The 
cells were cultured on 4-wells chamber slides and at 80% confluency slides were fixed with 
4% paraformaldehyde, blocked, and permeabilized. 
At first was performed an evaluation of specific epithelial antigens by staining for 
primary antibodies anti-E-cadherin (E-Cad, rabbit polyclonal, pre-diluted, Abcam, 
Cambridge, UK) and anti-panCytocheratin (panCK, mouse monoclonal, 1:20, 4°C o.n, 
DAKO). 
It was also detected the expression of Mesenchymal/stromal surface antigens as 
Vimentin (Vim monoclonal mouse, 1:50, o.n. 4°, Millipore) and CD44 (rat monoclonal, 1:50, 
4°C o.n, SantaCruz Laboratories) 
The presence of the surface antigens was revealed through the conjugation with anti-
mouse and anti-rabbit FITC-conjugated secondary antibodies (1:70 60’ 37°C, Sigma-Aldrich). 
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TRITC-conjugated secondary antibody was employed to detect the CD44 expression (anti rat, 
1:70 60’ 37°C, Sigma-Aldrich).  
Nuclei were counterstained by DAPI and cover slips mounted with Vectashield. 
 
Immunoperoxidase staining 
In order to confirm the pulmonary origin of these lines, the expression of the nuclear 
transcription factor Thyroid Transcription Factor 1 (TTF-1, rabbit monoclonal,1:20 4°C o.n., 
Abcam) was also detected by immunoperoxidase staining. 
After trypsinization, cell suspension was fixed with 4% paraformaldehyde for 40 
minutes, then the cells were suspended in a volume of buffer solution to obtain a density of 
105cells per spot. A cytofunnel was attached to a glass slide and slide carrier. The entire 
apparatus was inserted into a cytocentrifuge and the cell suspension was added and 
centrifuged at 240g for 5 minutes. 
The cell spot was then stained for anti-TTF1 antibody and then revealed by DAB 
reaction. 
 
Fluorescence In Situ Hybridization 
Fluorescence In Situ Hybridization (FISH) is a cytogenetic technique that combine 
fluorescence microscopy to molecular methods of in situ hybridization. FISH is used to detect 
and localize specific DNA sequence or chromosome, included sexual X and Y chromosome; 
for this purpose a fluorescent probe complementary to DNA researched sequence is used. 
For cytological staining, the cell population was cultured in a 4-well chamber slide 
until 80% confluency; then it was first fixed with 4% paraformaldehyde and pre-treated with 
saline solution of Saline Sodium Citrate buffer (SSC) 2x at double boiler for 30 minutes at 
80°C. After the preparations were wash-out twice with SSC 2x buffer and finally a 
dehydration with alcohol- increasing concentration of section was conduct before the addition 
of molecular probe.  
Specifically, for research of human sexual chromosomes was used a mix of two 
human specific Chromosome Enumeration Probe (CEP), complementary to centromeric 
region of X chromosome (Alpha-Satellite DNA, locus X p11.1-q11.1, Vysis, USA) and Y 
chromosome (Satellite III DNA, locus Yq12, Vysis, USA). 
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The specific hybridization protocol for these probes was performed with a HYBrite 
instrument and imply a first denaturation step of 10 minutes at 90°C and an overnight 
hybridization step at 42°C. After hybridization, samples were washed-out in SSC 2x buffer 
solution and a formamide solution at 42°C. The nuclei were counterstained with DAPI. 
The analysis was performed with a fluorescence microscope Olympus BX60. 
 
Ultrastructural Analysis  
 Cell lines of TEpC and Calu3 were also analyzed by Transmission Electron 
Microscopy (TEM) to detect structural and subcellular features. 
After trypsinization, both cell populations were fixed in Karnovsky solution (4% 
formaldehyde, 5% glutaraldehyde) for 90 minutes at room temperature. After washing with 
several changes of 0.1M phosphate buffer, PH 7.2, the pellets were embedded in agar to 
maintain themselves cohesive for the successive passages. 
The samples were postfixed in 1% osmium tetroxide (OsO4) for 90 minutes at room 
temperature and dehydrated by increasing concentration of alcohol. Following this procedure, 
samples were washed with propylene oxide and embedded in epoxy resin. Sections of 0.5 µm 
thickness were stained with methylene blue and safranin to select morphologically the field of 
interest. Subsequently, ultrathin sections were collected on a 300-mesh copper grid and, after 
staining with uranyl acetate and lead citrate, were qualitatively examined under a transmission 
electron microscope (Philips EM 208S). 
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In vivo studies 
Immunohistochemical analysis of a human lung adenocarcinoma 
In order to evaluate the effective epithelial origin of the TEpCs population obtained 
from lung adenocarcinoma, the histological case of interest was analyzed by 
immunohistochemical staining. 
Five-micrometer-thick sections obtained from formalin-fixed paraffine-embedded lung 
fragments were analyzed under fluorescence microscopy to determine the qualitative 
expression of specific surface and nuclear antigens already detected on isolated TEpCs. 
After sections deparaffination in Xylene and in a decreasing concentration of ethanol, 
rehydration and antigenic unmasking through a pre-treatment in citrate buffer (pH=6) by 
microwave, the samples were stained with several primary antibodies such as anti-E-Cad 
(rabbit polyclonal, prediluited, 4°C o.n., Abcam), anti-CD44 (rat monoclonal, 1:100, 37°C 90 
minutes, SantaCruz Laboratories), anti-panCK (mouse monoclonal,1:50, 37°C 90 minutes, 
DAKO) and anti-Vim (monoclonal mouse, 1:50, o.n. 4°C DAKO).  
Also the research of the mitosis marker Phosphohistone-H3 (phH3, rabbit polyclonal, 
1:100 o.n 4°C, Upstate, Lake Placid, NY, USA) was performed to evaluate the ratio of 
proliferating tumoral pan-CKpos population.  
The presence of the surface antigens was revealed through the conjugation with anti-
mouse and anti-rabbit FITC-conjugated secondary antibodies (1:70 60’ 37°C, Sigma-Aldrich). 
TRITC-conjugated secondary antibody was employed to detect the CD44 expression (anti rat, 
1:70 60’ 37°C, Sigma-Aldrich) and also panCK (anti mouse, 1:70 60’ 37°C, Sigma-Aldrich).   
Nuclei were counterstained by DAPI and cover slips mounted with Vectashield (Vector, USA) 
 
Experimental models 
In order to test the tumorigenic potential of isolated TEpCs and Calu3, a subcutaneous 
injection of these cell populations was administered in Balb-c NUDE female mice 
(CAnN.CG-Foxn1nu/Crl, Strain Code 194 Homozygous, Charles River Laboratory, Calco, 
Italy). 
Each animal was anaesthetized with a inhalation of vapour of ether; the cell pools 
were suspended in a saline buffer at the final density of 106cells/each animal; this solution 
was added to an equal quantity of Matrigel®  (BD Bioscence, Franklin Lakes, NJ) and 
subcutaneously injected on the right flank of each mouse using a 1ml-siringe. 
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A solid tumor was generated only in correspondence of the injection site. The growth 
of each tumor was evaluated by measuring tumor volume twice a week until animals sacrifice. 
The tumour volume was determined by the equation (lenght x Widht2) x 0,5. 
The animals were sacrificed approximately five weeks after tumor induction by 
cervical dislocation; the tumors were collected for both cell isolation and histological 
assessment. 
 
Morphometrical analysis of tumour xenografts. 
After paraffin inclusion, from the tumoral nodules were obtained five-micrometer-
thick sections stained with Haematoxylin and Eosin (H&E), Masson’s Trichrome or used for 
immunohistochemistry.  
In order to compare the histological features of xenograft tumors with the primary 
human cancer an histological evaluation with H&E stained was performed.  
On the sections stained by Masson’s Trichrome was also made the morphometric 
evaluation of nodules composition in terms of area occupied by collagen or neoplastic 
formation. Microphotograph of total nodule were captured by an optical microscope 
connected to a digital camera with final magnification of 40X. Subsequently, the area 
occupied by collagen deposition or neoplastic tissue was evaluate by image analysis software 
(Image pro-plus 4.0, Media Cybernetics, USA). A macroscopic image of the whole nodule 
was captured to determine the total area.  
Moreover, for the neoplastic tissue was also obtain the percentage of glandular and 
luminal area respect to the total neoplastic area 
 
Immunohistochemical analysis of tumour xenografts. 
 Additional data about the morphological features of both induced- and human cancers 
were also produced by immunohistochemical detection of surface and nuclear antigens 
described above in order to compare the tumoral and stromal organization of tumor xenografts 
with the primary human cancer. 
Five-micrometer-thick sections obtained from formalin-fixed paraffine-embedded 
samples were analyzed under fluorescence microscopy to determine the qualitative expression 
of specific surface and nuclear antigens already investigated on isolated TEpCs. 
After sections deparaffination in Xylene and in a decreasing concentration of ethanol, 
rehydration and antigenic unmasking through a pre-treatment in citrate buffer (pH=6) by 
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microwave, the samples were stained with several primary antibodies such as anti-E-Cad 
(rabbit polyclonal, pre-diluted, 4°C o.n., Abcam), anti-panCK (mouse monoclonal,1:50, 37°C 
90 minutes, DAKO), anti-CD44 (rat monoclonal, 1:100, 37°C 90 minutes, SantaCruz 
Laboratories) and anti-Vim (monoclonal mouse, 1:50, o.n. 4°C DAKO).  
Also for the xenografts the detection of the mitosis marker Phosphohistone-H3 (phH3, 
rabbit polyclonal, 1:100 o.n 4°C, Upstate, Lake Placid, NY, USA) was performed to evaluate 
the ratio of proliferating tumoral pan-CKpos population. 
The presence of the surface antigens was revealed through the conjugation with anti-
mouse and anti-rabbit FITC-conjugated secondary antibodies (1:70 60’ 37°C, Sigma-Aldrich). 
TRITC-conjugated secondary antibody was employed to detect the CD44 (anti rat, 1:70 60’ 
37°C, Sigma-Aldrich) and panCK (anti mouse, 1:70 60’ 37°C, Sigma-Aldrich) expressions. 
Nuclei were counterstained by DAPI and cover slips mounted with Vectashield 
(Vector, USA) 
 
Fluorescence In Situ Hybridization 
FISH analysis for the detection of human sexual chromosomes was used to tracking 
the injected human cells in the tumour xenograft samples. 
Respect to the FISH protocol described above for the cell samples, the use of this 
technique on paraffin-embedded sections requires appropriate protocol devices.  
The first step for these samples is the deparaffination in Xylene and in a decreasing 
concentration of ethanol with subsequent rehydration. The sections were then process by acid 
hydrolysis with HCl 0,2N for 20 minutes at room temperature and pre-treated with a saline 
solution of Saline Sodium Citrate buffer (SSC) 2x at double boiler for 30 minutes at 80°C. 
Subsequently, in order to denature cellular proteins and promote the binding of nucleic acid to 
hybridization probe, an enzymatic digestion with Proteinase K was performed at 37°C. 
Finally, a post fixation with 4% formaldehyde and alcohol dehydration of section was conduct 
before the addition of molecular probe. 
For research of human sexual chromosomes was used a mix of two human specific 
Chromosome Enumeration Probe (CEP), complementary to centromeric region of X 
chromosome (Alpha-Satellite DNA, locus X p11.1-q11.1, Vysis, USA) and Y chromosome 
(Satellite III DNA, locus Yq12, Vysis, USA). 
The specific hybridization protocol for these probes was performed with a HYBrite 
instrument and imply a first denaturation step of 10 minutes at 90°C and an overnight 
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hybridization step at 42°C. After hybridization, samples were washed-out in SSC 2x buffer 
solution and a formamide solution at 42°C. The nuclei were counterstained with DAPI. 
The analysis was performed with a fluorescence microscope Olympus BX60 at 100x 
magnification with oil immersion objective. 
 
Isolation and in vitro expansion of neoplastic cells from xenograft tumours. 
 After tumor excision, part of each nodule was utilized for the re-isolation of tumor 
injected cells. The tumoral nodules were excised in sterile condition and processed separately 
for each group (Calu-3 or TEpC cell injection) under hood at laminar flow.  
 After removal of surrounding epidermal and connective tissue, one-half of each nodule 
was fixed in 4% formaldehyde, while the remain part was washed-out with a saline buffer and 
then processed for the cell isolation.  
As for the human lung fragments, nodules were firstly minced with scissors and then 
put into a collagenase/dispase solution (C/D, 1mg/ml, ROCHE) for 40 minutes in a shaking 
bath at 37°C. At the end of enzymatic digestion, the tissue fragments were removed using a 
nylon filter with pores of 100 µm and the cell suspension was centrifuged at 240g for 5 
minutes.  
For the cells rescued from the nodules formed by Calu-3, the medium culture was 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 1%, P/S, 1% 
I/T/S and 1% NEAA. On the other hand the pellet obtained from TEpC nodules digestion was 
suspended in complete DMEM medium supplemented with specific growth factors as 10 
ng/ml of b-FGF and 10 ng/ml of EGF. Both cell suspension were seeded in 6 well plates at 
37°C-5% CO2. 
Twenty-four hours after plating the debris and the non-adherent cells were removed by 
washing twice with PBS; fresh culture medium was then added to cell culture and then 
changed twice a week.  
Daily observation of cellular monolayers using an inverted microscope (Olympus 
CK40, Japan) pointed out the growth of two different adherent cell populations, one with 
fibroblast-like shape and one with epithelial characteristics. 
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Statistical analysis 
The SPSS statistical package was used (SPSS, Chicago, IL, USA). Normal distribution 
of variables was checked by means of the Kolmogorov-Smirnov test. Statistics of variables 
included mean ± standard error (S.E.M.), paired Student t-test, one-way analysis of variance 
(post-hoc analyses: Bonferroni test or Games-Howell test, when appropriate). Statistical 
significance was set at p<0.05. 
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Results and Discussion 
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 Study Population 
The patient population consisted of 86 subjects undergoing lobectomy for lung cancer.  
All samples recruited for the study were classified by diagnosis and histopathology of 
the disease, sex, age and smoking status (Table 1). The diagnosis performed by pathologists 
documented 52 Adenocarcinoma, 22 Squamous cell carcinoma (SCC) and 12 Neuroendocrine 
tumor samples. 
Related to sex incidence, our data show an equal incidence of neuroendocrine 
carcinoma for both male and female whereas the other two histological subtypes show 
dominant incidence in male sex, especially SCC, that seems strictly related to smokers status 
more than adenocarcinoma.  
 
Table 1 Case Study Classification 
 
In vitro study 
Cell isolation and enrichment 
After the mechanical and enzymatic digestion of healthy and neoplastic tissue we have 
obtained an heterogeneous population of adherent cells that we could expand in vitro for 
several passages. In particular basing on their morphologies we have identified two main 
populations: a stromal pool with a fibroblast-like morphology, and one with the classical 
epithelial morphology (Figure 1A).  
The stromal population was easily maintained and expanded in vitro: these cells grow 
quickly and reach confluence approximately five days after plating. Both healthy and tumor 
stromal cells were phenotipically characterized by FACS and immunocytochemical analysis 
(data not shown). 
The epithelial population was obtained from cancer nodule. In relation to lung cancer 
type, the isolated morphologies were different for shape and growth characteristic (Figure 
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1B,C). Generally, all these epithelial populations grow in colonies and slowly when compared 
to stromal lines. 
Although the isolation protocol seems to be appropriate for the cell isolation from 
several lung cell compartments, the expansion and maintenance of epithelial cells in culture 
require some adjustments. 
Anyway we were able to expand and characterized one of these epithelial cell lines, 
derived from a lung adenocarcinoma of a 58-years old male (Figure 2A). 
In particular, the patient is an 12-years ex-smoker (90 pack/year); he was submit to 
right inferior lobectomy with a diagnosis of lung mucinous-type adenocarcinoma, classified 
after histological analysis at pT1aN2 pathological status, staging IIIa. The patient was no 
affected by previous malignancies and no treated with neoadjuvant chemotherapy. 
The isolated cells were compared to Calu-3 population for their similar epithelial and 
cancer origin (Figure 2B). A preliminary evaluation of cell growth show an equal exponential 
trend, even if TEpCs are fewer than Calu-3, probably due to different cell doubling time 
(Figure 2C, D). 
 
FACS analysis 
The epithelial nature of isolated TEpCs was first evaluated by FACS analysis at fourth 
passage of expansion (p4): the expression of EpCAM was detected in 95% of analyzed cells. 
Moreover, TEpC expressed the stem cell marker CD133 (35%) and the mesenchymal 
adhesion molecule CD44 (88%). Low or none positive cell for CD117 and mesenchymal 
markers were detected, except for CD73 (85%) (Figure 3).  
 
Immunocytochemical analysis 
More evidences of epithelial nature of TEpCs were obtained by immunocytochemical 
staining for specific epithelial markers such as panCK and E-Cad. Their expression was 
detected on the surface of almost all cells, especially in growing colonies (Figure 4A, B). 
The mesenchymal markers Vimentin and CD44 were evaluated to assess if the in vitro 
culture conditions could influence the EMT process. Vimentin expression in TEpCs at p4 was 
detected only in few cells grown isolated from colonies whereas the adhesion molecule CD44 
was localized on a high fraction of adherent cells, according to FACS analysis (Figure 4C, D). 
The lung epithelial origin was confirmed by TTF-1 nuclear expression revealed by 
immunoperoxidase staining (Figure 4E). 
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These qualitative analysis were performed simultaneously in Calu-3: this cell line has 
the same source of isolated TEpC and then was used as positive control. The epithelial and 
mesenchymal markers show a similar quantitative and qualitative pattern distribution in both 
cell lines. Only the CD44 staining show a preferential expression surrounding the cell 
colonies. (Figure 5 A-E) 
 
FISH analysis on isolated TEpCs 
One of the characteristic of aggressive neoplastic cells is the presence of genetic 
anomalies; in particular, for the cell lines deriving from male patient, an extended 
proliferation causes the loss of Y sex chromosome and subsequent X-polysomy. The Calu-3 
cell line of NSCLC characteristically displays this genetic tract (Figure 6B).  
FISH analysis on our primary culture of TEpC at p4 passage was performed to 
evaluate potential sex chromosomes abnormality (Figure 6A). Our results shows that 90 % of 
TEpC carry X and Y chromosomes and only 10% of cells Y chromosome was undetectable. 
 
Ultrastructural analysis 
TEM analysis of cultured cells allowed us to evaluate their specific ultrastructural 
features.  
TEpC and Calu3 appear similar in terms of shape and subcellular characteristic such 
as nuclear chromatin condensation and the presence of numerous intracytoplasmic vescicles; 
cell dimensions were slightly increased in Calu-3 compared to TEpC (Figure 7A-D) 
In both cell preparations we were able to document one of the ultrastructural features 
of adenocarcinoma “signet ring” consisting of a large intracytoplasmic empty vesicle (Figure 
7E, F). 
Moreover, mitotic figures were found in TEM samples, as an additional feature of the 
high replicative capacity of neoplastic cells (Figure 7G,H).  
Although cells have been treated with trypsin to obtain TEM samples, some adherent 
intercellular junctions were still present and well observable at higher magnification (Figure 
8). 
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Evaluation of EMT activation  
In order to evaluate if the in vitro amplification and expnasion induced phenotypic 
changes in isolated TEpC, the cytofluorimetric and immunocytochemical analysis were 
performed on cultured cells at higher passages (p14). Data were compared to that obtained at 
p4. 
The quantitative FACS analysis shows a slight reduction on the expression of the 
epithelial marker EpCam (90% versus 95% of p4) and of the mesenchymal-like marker CD44 
(75% vs 88% p4). A significant increase from 35% at p4 to 73% at p14 was measured in the 
stem/progenitor marker CD133, and in the mesenchymal marker CD105 that was expressed 
by almost half of analyzed population at p14 (Figure 9). 
The ICC staining for all markers described above shows similar results to those 
previously described, except for the increasing expression of fibroblast surface antigen 
Vimentin and the simultaneous decrease of epithelial marker EpCam expression. These 
observation taken together may be explained by in vitro activation of EMT process (Figure 10 
A-E). 
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In vivo studies 
Immunohistochemical analysis of primary human lung cancers 
In order to confirm that the TEpCs isolated from fresh lung cancer derive from 
epithelial cancer cell we have analyzed the histological samples of the specific clinical case 
(Figure 11A,B) 
The specific epithelial markers E-Cad and panCK, highly expressed in the cytologic 
samples, have been largely detected also in histological preparations specifically in the 
epithelial cells that form the neoplastic glands (Figure 11C, D). The stromal markers CD44 is 
clearly expressed by neoplastic glands, while Vimentin was predominantly present in the peri-
tumoral stroma (Figure 11E). 
Several mitotic figures of epithelial cells were documented by double staining for 
phH3 and panCK (Figure 11F). 
 
Experimental models 
One of the principal features of a defined Cancer Initiating Cell (CIC) population is 
the tumorigenic potential, in other word their capacity to regenerate a neoplastic mass 
histologically equal to the original ones in several serial xenografts. 
Experimental models of xenografts allowed us to test this property for isolated TEpCs, 
whereas for Calu-3 population it was largely documented33,34.  
After the injection of the same number of TEpCs and Calu-3 cells, the tumor growth 
was evaluated twice a week from the injection to animal sacrifice. The tumor volume initially 
decreased due to Matrigel® reabsorption. Then, both types of neoplastic cells gave rise to a 
solid mass with a similar size (Figure 12A-E). 
 
Morphometric analysis of tumour xenografts. 
A morphometric evaluation of tumour mass was assessed by H&E and Masson’s 
trichrome staining. The nodules generated by Calu-3 and TEpC cells showed the typical 
glandular feature of adenocarcinoma clearly seen in histologic samples (Figure 13A-D). 
The evaluation of tumour composition on sections stained with Masson’s trichrome 
revealed that TEpC nodules were composed of 31% by connective tissue and 68% by 
neoplastic structures; the latter was further subdivided in glandular and luminal area, that 
occupy 92% and 4% of tumor area, respectively. When compared to TEpC xenografts, the 
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morphometric analysis of Calu-3 nodules showed an increased collagen deposition (56%) and 
a subsequent reduction of tumor area (43%), which was composed of epithelial cells (83%) 
and luminal area (16% ) (Figure 13E,F). 
 
Characterization of tumour xenografts. 
On sections from nodules excised from both experimental groups, 
immunohistochemical and FISH analysis were performed in order to compare tumour 
xenografts with the primary lung cancer. 
 In particular, the IHC analysis of xenograft sections was performed to confirm that 
the solid mass excised from nude mice was a tumor generated from injected human cells with 
an adenocarcinoma provenance. 
Compared with the clinical case, an equal distribution pattern of both epithelial and 
stromal markers was observed in the TEpC nodules (Figure 14A-D). 
An additional evidence of human origin of induced tumor was obtained from the FISH 
analysis for human sex chromosomes. The typical X polysomy associated to Calu-3 and the 
presence of XY chromosomes in TEpC generated xenografts were detected in cells 
constituting the glands of adenocarcinoma. The double staining of sex chromosomes and 
panCK confirmed the original phenotype of the injected populations (Figure 14E). 
The analysis performed in parallel with Calu-3 xenografts, documented a similar  
morphologic features of two induced tumours (Figure 15A-C). 
 
Re-isolation of neoplastic cells from xenograft tumours. 
Another step to prove the tumorigenic potential of TEpCs is the serial re-isolation and 
re-injection of cells from xenografts. For this purpose, a small fragment from each nodule of 
both experimental groups was processed for cell isolation. 
The enzymatic digestion allowed us to obtain two main populations, one fibroblast-
like of murine origin and one with epithelial morphology similar to injected cells (Figure 
17A, B). 
The expansion of these two populations is ongoing; obviously, both epithelial 
populations must be tested for their immunophenotypic properties and ability to generate 
tumours in secondary transplants. 
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Conclusion 
The aim of our study was to identify and isolate a subpopulation of cancer initiating 
stem cells that is responsible of the maintenance and growth of the tumour. CICs can be 
recognized principally for their functional properties of self-renewal, aggressiveness and 
ability to sustain the cancer growth and metastasis. Furthermore, they are able to regenerate in 
vivo a neoplasia with the same phenotypic characteristics of the primitive cancer. This 
capacity implies the activation of molecular and genetic tissue-specific mechanisms which are 
responsible for the onset and progression of tumours. 
Our attention was focused on one of the most aggressive human malignancies, the 
lung cancer. 
The poor prognosis usually related to this cancer is likely due to the lack of knowledge 
of its pathogenetic bases and therefore the therapeutic approach is quite frustrating. 
Preliminary data obtained from our study seem promising. Compared with a control 
cancer line Calu-3, the cancer epithelial cells isolated from a human primary adenocarcinoma 
showed an high grade of similarity, both phenotypic and functional. 
In particular, the in vitro phenotypic changes in relation to epithelial and mesenchymal 
markers expression may be investigated in order to understand the signaling pathways and the 
micro-environmental factors implicated in epithelial-to-mesenchymal transition. 
In regard of the functional properties, the experimental model of xenografts have 
confirmed that the isolated cancer pool possess a tumorigenic potential. The strong histotypic 
similarities of xenografts with the primary lung cancer reinforce our initial hypothesis of the 
stem epithelial nature of the isolated population. Moreover, the TEpC-induced xenografts 
were integrated with the stromal murine compartment.  
In conclusion, the isolation and in vitro expansion of a primary lung cancer cell lines 
may be the first step for the characterization of a CICs subpopulation responsible of cancer 
progression. Its identification in lung cancer may have two potential implications: on one 
hand the possibility to develop a personalized therapy with new drugs highly specific for this 
subpopulation; on the other hand the phenotypic characterization of these cells could be the 
first step for their selective isolation followed by in vivo tumorigenic properties and studies on 
their molecular and genetic profile. 
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Figure 1: Phase contrast images showing the heterogeneous population (A) of adherent cells 
obtained from lung cancer fragments. Different morphologies of epithelial cells isolated from 
neoplastic lung fragments are shown in panel B and C. 
Scale bars A  and B :500 µm; C: 200 µm 
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Figure 2: Tumour Epithelial Cell (TEpC) population isolated from a human lung 
adenocarcinoma (A). Calu-3 cell line is shown in B as control. Graphs show in vitro 
evaluation of cell growth of TEpC (C) and Calu-3 (D). Scale bars 500µm 
36 
 
 
Figure 3: FACS analysis on TEpC at passage 4 of in vitro amplification 
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Figure 4: Immunocytochemical analysis of isolated TEpCs. The expression of epithelial 
markers E-Cad shown in red fluorescence (A) and panCK (green fluorescence, B) was present 
in almost all cells. The mesenchymal markers Vimentin (C) and CD44 (D) are also shown by 
green and red fluorescence, respectively. Nuclei are recognized by the blue fluorescence of 
DAPI. 
The lung transcription factor TTF-1 is documented by immunoperoxidase staining (E).  
Scale bars A and C 30 µm; B, D and E: 50 µm 
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Figure 5: Immunocytochemical analysis of Calu-3. The expression of epithelial markers E-
Cad shown in red fluorescence (A) and panCK in green fluorescence (B) was detected on 
almost all cells. The mesenchymal markers Vimentin (C) and CD44 (D) are also shown by 
green and red fluorescence, respectively. The lung transcription factor TTF-1 is shown by 
green fluorescence (E). Nuclei are recognized by the blue fluorescence of DAPI.  
Scale bars A, B, C and D :50 µm; E :30 µm 
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Figure 6: FISH analysis on cultured TEpC (A) and Calu-3 (B) cell lines. Sex X and Y 
chromosomes are visualized by red and green fluorescence, respectively. Nuclei are 
recognized by the blue fluorescence of DAPI. Scale bars:50 µm 
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Figure 7: Ultrastructural analysis of TEpC and Calu-3. TEM images show similar subcellular 
characteristics, as intracytoplasmic vacuoles and nuclear chromatin condensation (A-D). 
Panels E and F show typical adenocarcinoma “signet ring” feature in both TEpC and Calu-3 
samples. Mitotic figures in TEpC (G) and Calu-3(H) are illustrated. 
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Figure 8: Ultrastructural analysis of TEpC and Calu-3. A and B TEM images show the 
presence of preserved intercellular adherence junctions in TEpC and Calu-3, respectively. 
Adherence junctions are showed at higher magnification in A1 and B1 (arrowheads). 
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Figure 9: FACS analysis on TEpC at passage 14 of in vitro amplification 
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Figure 10: Phase contrast image of TEpC population at p14 (A). Immunocytochemical 
characterization of these cells by the detection of epithelial markers E-Cad (B) and panCK (C) 
shown in red and green fluorescence, respectively. The mesenchymal markers Vimentin (D, 
green fluorescence) and CD44 (E, red fluorescence) were also detected. 
Scale bars A: 500 µm, B and C :30 µm; D and E :50 µm 
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Figure 11: Human primary lung adenocarcinoma. Hystological preparations of lung cancer 
tissue stained by H&E (A) and Masson’s Trichrome (B). Epithelial glands are positive for E-
Cad (C, green fluorescence) and CD44 (D, red fluorescence). In panel E, double 
immunostaining for panCK (red fluorescence) and Vim (green fluorescence) illustrates 
neoplastic glands surrounded by stromal cells. Panel F: mitotic divisions in panCK positive 
(red fluorescence) cells are shown by the green fluorescence of phosphohistone H3.  
Scale bars A-C :100 µm, D-E :50 µm; F :30 µm 
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Figure 12: Macrophotographs of nodules excised from TEpC (A) and Calu-3 (B) injected 
mice. Hystological analysis was performed on Masson’s trichrome staining of sections from 
TEpC (C) and Calu-3 (D) tumour xenografts. The line graph highlights the in vivo tumour 
growth in the two experimental groups. Scale bars :500µm. 
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Figure 13: Hystostological analysis of tumour xenografts of TEpC and Calu-3 by H&E (A 
and B) and Masson’s Trichrome (C and D). Morphometric quantification of nodule 
composition and fractional area of neoplastic structures are reported in graph E and F, 
respectively. Scale bars :100 µm 
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Figure 14: Sections of TEpC nodule. Immunohistochemical detection of E-Cadherin (A, 
green) and CD44 (B, red). Microphotograph in C shows Pan-cytokeratin (red fluorescence) 
and Vimentin (green fluorescence) expression. Mitotic divisions in panCK postitive (red 
fluorescence) cells are shown by the green fluorescence of phosphohistone-H3 (D). Panel E 
shows the localization of Human sexual chromosomes XY in the tumour cells stained for 
panCK (green fluorescence). Nuclei are recognized by the blue fluorescence of DAPI. Scale 
bars: 50µm 
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Figure 15: Sections of Calu-3 nodule. Immunohistochemical detection of Vimentin and 
CD44 showed in green and red fluorescence, respectively (A). Mitotic cell positive for phH3 
(green fluorescence) and panCK (red fluorescence) are detected in panel B. 
Panel C: FISH analysis of human X chromosome (red fluorescence) associated to panCK 
staining (green fluorescence) to confirm the human tumoral origin of xenografts. 
Nuclei are recognized by the blue fluorescence of DAPI. Scale bars A and B: 100 µm; C: 
50µm  
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Figure 16: Phase contrast images of TEpC (A) and Calu-3 (B) re-expanded after their 
isolation from excised tumour xenografts. Scale bars 200 µm 
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